https://www.selleckchem.com/products/ZLN005.html
3±1.4. The mean number of medications used at 12, 18 and 24 months was respectively 2.6±1.5, 2.5±1.4 and 2.2±1.5. Postoperative complications included cystic macular edema (n=2), hypotony maculopathy (n=1), fibrinous/uveitic reaction (n=1) and rejection of corneal graft (n=1), all reversible after treatment. One patient developed persisting hypotony in the late postoperative period. Conclusion Micropulse TSCPC is a safe and effective treatment for lowering both IOP and the number of IOP-lowering medications. Micropulse TSCPC can also be
Like
Comment
Share
